Production (Stage)
Esperion Therapeutics, Inc.
ESPR
$1.17
-$0.03-2.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -153.22M | -51.75M | -86.77M | -98.50M | -86.51M |
| Total Depreciation and Amortization | 89.00K | 63.00K | 42.00K | 42.00K | 83.00K |
| Total Amortization of Deferred Charges | 1.76M | 1.50M | 1.76M | 1.74M | 1.72M |
| Total Other Non-Cash Items | 77.96M | 87.06M | 94.48M | 103.23M | 58.51M |
| Change in Net Operating Assets | -26.70M | -60.53M | -35.27M | -16.27M | -1.11M |
| Cash from Operations | -100.11M | -23.65M | -25.76M | -9.76M | -27.30M |
| Capital Expenditure | -244.00K | -317.00K | -317.00K | -150.00K | -73.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | 0.00 | 17.50M |
| Cash from Investing | -244.00K | -317.00K | -317.00K | -150.00K | 17.43M |
| Total Debt Issued | 99.73M | 99.73M | -- | -- | -- |
| Total Debt Repaid | -210.09M | -210.09M | -- | -- | -- |
| Issuance of Common Stock | 9.60M | 106.04M | 115.09M | 114.56M | 109.81M |
| Repurchase of Common Stock | -343.80M | -343.80M | -343.75M | -343.77M | -20.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 432.94M | 434.60M | 284.62M | 289.96M | -18.21M |
| Cash from Financing | -11.62M | 86.48M | 55.96M | 60.74M | 91.57M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -111.98M | 62.51M | 29.88M | 50.83M | 81.70M |